Abiraterone for “STAMPEDE-Like” cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?
For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.
Authors
- Archi Agrawal (ORCID: https://orcid.org/0000-0003-1608-7780)
- Pallavi Singh (ORCID: https://orcid.org/0000-0002-6041-7479)
- Gagan Prakash (ORCID: https://orcid.org/0000-0003-1722-4337)
- Priyamvada Maitre (ORCID: https://orcid.org/0000-0002-8878-7914)
- Vedang Murthy (ORCID: https://orcid.org/0000-0001-6011-9319)
- Prashant Nayak (ORCID: https://orcid.org/0000-0001-5852-0170)
- Amit Joshi
- Asesh Samanta
Institutions
- Homi Bhabha National Institute (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1038/s41391-025-00983-8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00